Safety considerations with fenofibrate/simvastatin combination

Expert Opinion on Drug Safety

Volumn 14, Issue 9, 2015, Pages 1481-1493

  Filippatos, Theodosios D ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adverse effects; Cardiovascular disease; Drug interactions; Fenofibrate; Mixed dyslipidemia; Pharmacokinetics; Safety; Simvastatin; Tolerability

Indexed keywords

CREATININE; FENOFIBRATE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; SIMVASTATIN; ANTILIPEMIC AGENT; DRUG COMBINATION; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AMINO ACID BLOOD LEVEL; ARTICLE; CANCER INCIDENCE; CANCER RISK; CATARACT; CHOLESTEROL BLOOD LEVEL; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DERMATOMYOSITIS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EOSINOPHILIA; HUMAN; INTERSTITIAL LUNG DISEASE; LUPUS LIKE SYNDROME; META ANALYSIS (TOPIC); MYOPATHY; MYOSITIS; PHOTOSENSITIVITY; PLEURA EFFUSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SIDE EFFECT; URTICARIA; VASCULITIS; COMPARATIVE STUDY; DRUG COMBINATION; DRUG INTERACTION; DYSLIPIDEMIAS; RISK FACTOR;

DRUG COMBINATIONS; DRUG INTERACTIONS; DYSLIPIDEMIAS; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SIMVASTATIN;

EID: 84939799260     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1056778     Document Type: Article

References (169)

1. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: Prospective metaanalysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78
3. Elisaf MS, Nikas N. Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs-the CEPHEUSGreece survey. Angiology 2010; 61: 465-74
4. Leiter LA, Lundman P, da Silva PM, et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011; 28: 1343-51
5. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-8
6. Gazi IF, Milionis HJ, Filippatos TD, et al. Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women. Diabetes Metab Res Rev 2008; 24: 223-30
7. Ling H, Burns TL, Hilleman DE. Novel strategies for managing dyslipidemia: treatment beyond statins. Postgrad Med 2012; 124: 43-54
8. Filippatos TD. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovasc Drugs Ther 2012; 26: 245-55
9. Filippatos TD, Elisaf MS. Combination drug treatment in obese diabetic patients. World J Diabetes 2010; 1: 8-11
10. Agouridis AP, Rizos CV, Elisaf MS, et al. Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? Rev Diabet Stud 2013; 10: 171-90
11. Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother 2011; 12: 1945-58
12. Agouridis AP, Tsimihodimos V, Filippatos TD, et al. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids 2011; 46: 521-8
13. Agouridis AP, Tsimihodimos V, Filippatos TD, et al. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother 2011; 12: 2605-11
14. Pedersen TR, Tobert JA. Simvastatin: A review. Expert Opin Pharmacother 2004; 5: 2583-96
15. Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs 2008; 17: 1599-614
16. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993; 24: 195-202
17. Vickers S, Duncan CA, Vyas KP, et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990; 18: 476-83
18. Vickers S, Duncan CA, Chen IW, et al. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990; 18: 138-45
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
20. Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009; 15: 479-89
21. Filippatos TD, Mikhailidis DP. Statins and heart failure. Angiology 2008; 59: 58S-61S
22. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-16
23. Rizzo M, Berneis K. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin 2007; 23: 1103-11
24. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005; 21: 1997-2006
25. Hiukka A, Leinonen E, Jauhiainen M, et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 2007; 50: 2067-75
26. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007; 193: 428-37
27. Agouridis AP, Filippatos TD, Derdemezis CS, et al. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des 2010; 16: 3401-16
28. Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring) 2009; 17: 504-9
29. Filippatos TD, Liberopoulos EN, Kostapanos M, et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 2008; 10: 476-83
30. Belfort R, Berria R, Cornell J, et al. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 2010; 95: 829-36
31. Filippatos T, Tsimihodimos V, Kostapanos M, et al. Analysis of the 6-month effect of orlistat, alone or in combination with fenofibrate, administration on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. J Clin Lipidol 2008; 2: 279-84
32. Florentin M, Liberopoulos EN, Filippatos TD, et al. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: A pilot study. Expert Opin Pharmacother 2008; 9: 2741-50
33. Uetake D, Ohno I, Ichida K, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med 2010; 49: 89-94
34. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-6
35. Sacks FM. After the fenofibrate intervention and event lowering in diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol 2008; 102: 34L-40L
36. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 2007; 370: 1687-97
37. Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): A prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-8
38. Kayikcioglu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 1999; 83: 1135-7
39. Agouridis AP, Liberopoulos EN, Kostapanos MS, et al. New-onset extremely low levels of high-density lipoprotein cholesterol. J Clin Lipidol 2012; 6: 593-5
40. Derosa G, Maffioli P, Salvadeo SA, et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin 2009; 25: 1973-83
41. Stefanutti C, Bucci A, Di Giacomo S, et al. Efficacy, safety and tolerability of combined low-dose simvastatinfenofibrate treatment in primary mixed hyperlipidaemia. Clin Drug Investig 2004; 24: 465-77
42. Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol 2011; 107: 1010-18
43. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006; 48: 396-401
44. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005; 95: 462-8
45. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009; 1791: 327-38
46. Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005; 51: 2264-73
47. Tzotzas T, Filippatos TD, Triantos A, et al. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr Metab Cardiovasc Dis 2008; 18: 477-82
48. Tsimihodimos V, Kakafika A, Tambaki AP, et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoBcontaining lipoproteins. J Lipid Res 2003; 44: 927-34
49. Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007; 27: 2236-43
50. May HT, Anderson JL, Pearson RR, et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol 2008; 101: 486-9
51. Tsimihodimos V, Liberopoulos E, Elisaf M. Pleiotropic effects of fenofibrate. Curr Pharm Des 2009; 15: 517-28
52. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006; 3: 144-53
53. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-74
54. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-44
55. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120-2
56. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81
57. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12, 064 survivors of myocardial infarction: A double-blind randomised trial. Lancet 2010; 376: 1658-69
58. Taher TH, Dzavik V, Reteff EM, et al. Tolerability of statin-fibrate and statinniacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol 2002; 89: 390-4
59. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90
60. Niemi M, Pasanen MK, Neuvonen PJ. Organic Anion Transporting Polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011; 63: 157-81
61. Ramsey LB, Johnson SG, Caudle K, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014; 96: 423-8
62. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705
63. de Denus S, Spinler SA, Miller K, et al. Statins and liver toxicity: A meta-analysis. Pharmacotherapy 2004; 24: 584-91
64. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/ AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2014; 63: 2889-934
65. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-609
66. Musso G, Cassader M, Gambino R. Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: An update. Curr Opin Lipidol 2011; 22: 489-96
67. Kostapanos MS, Kei A, Elisaf MS. Current role of fenofibrate in the prevention and management of nonalcoholic fatty liver disease. World J Hepatol 2013; 5: 470-8
68. Leiss O, Meyer-Krahmer K, von Bergmann K. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. J Lipid Res 1986; 27: 713-23
69. von Bergmann K, Leiss O. Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia. Eur J Clin Invest 1984; 14: 150-4
70. Caroli-Bosc FX, Le Gall P, Pugliese P, et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 2001; 46: 540-4
71. Duane WC, Hunninghake DB, Freeman ML, et al. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988; 8: 1147-50
72. Wu BU, Pandol SJ, Liu IL. Simvastatin is associated with reduced risk of acute pancreatitis: findings from a regional integrated healthcare system. Gut 2015; 64: 133-8
73. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207
74. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-42
75. Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009; 204: 483-90
76. Navarese EP, Szczesniak A, Kolodziejczak M, et al. Statins and risk of new-onset diabetes mellitus: is there a rationale for individualized statin therapy? Am J Cardiovasc Drugs 2014; 14: 79-87
77. Yada T, Nakata M, Shiraishi T, et al. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999; 126: 1205-13
78. Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881-92
79. Koh KK, Quon MJ, Han SH, et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008; 31: 776-82
80. Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013; 111: 1123-30
81. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 2012; 380: 565-71
82. Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013; 61: 148-52
83. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011; 305: 2556-64
84. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90
85. Buldak L, Dulawa-Buldak A, Labuzek K, et al. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. Int J Clin Pharmacol Ther 2012; 50: 805-13
86. Li XM, Li Y, Zhang NN, et al. Combination therapy with metformin and fenofibrate for insulin resistance in obesity. J Int Med Res 2011; 39: 1876-82
87. Koh KK, Quon MJ, Shin KC, et al. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis 2012; 220: 537-44
88. Koh KK, Quon MJ, Lim S, et al. Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. Atherosclerosis 2011; 214: 144-7
89. Shin SJ, Lim JH, Chung S, et al. Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats. Hypertens Res 2009; 32: 835-45
90. Kei A, Liberopoulos E, Elisaf M. Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia. World J Diabetes 2013; 4: 365-71
91. Milionis HJ, Papakostas J, Kakafika A, et al. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003; 43: 825-30
92. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202
93. Dionisio N, Jardin I, Salido GM, et al. Homocysteine, intracellular signaling and thrombotic disorders. Curr Med Chem 2010; 17: 3109-19
94. Zhou J, Austin RC. Contributions of hyperhomocysteinemia to atherosclerosis: Causal relationship and potential mechanisms. Biofactors 2009; 35: 120-9
95. Di Minno MN, Tremoli E, Coppola A, et al. Homocysteine and arterial thrombosis: Challenge and opportunity. Thromb Haemost 2010; 103: 942-61
96. Jiang S, Chen Q, Venners SA, et al. Effect of simvastatin on plasma homocysteine levels and its modification by MTHFR C677T polymorphism in Chinese patients with primary hyperlipidemia. Cardiovasc Ther 2013; 31: e27-33
97. Glueck CJ, Smith D, Gandhi N, et al. Treatable high homocysteine alone or in concert with five other thrombophilias in 1014 patients with thrombotic events. Blood Coagul Fibrinolysis 2015. [Epub ahead of print]
98. Jardine MJ, Kang A, Zoungas S, et al. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ 2012; 344: e3533
99. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-75
100. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-88
101. Bazzano LA, Reynolds K, Holder KN, et al. Effect of folic acid supplementation on risk of cardiovascular diseases: A metaanalysis of randomized controlled trials. JAMA 2006; 296: 2720-6
102. Tsimihodimos V, Bairaktari E, Elisaf M. Fibrate-induced increase in serum urea and creatinine levels. Nephrol Dial Transplant 2002; 17: 682
103. Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: An overview. Eur J Clin Invest 2013; 43: 522-31
104. Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011; 54: 280-90
105. Ting RD, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care 2012; 35: 218-25
106. Ansquer JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45: 485-93
107. Slinin Y, Ishani A, Rector T, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: A systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis 2012; 60: 747-69
108. Mychaleckyj JC, Craven T, Nayak U, et al. Reversibility of fenofibrate therapyinduced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 2012; 35: 1008-14
109. Bonds DE, Craven TE, Buse J, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia 2012; 55: 1641-50
110. Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002; 92: 536-41
111. Forsblom C, Hiukka A, Leinonen ES, et al. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 2010; 33: 215-20
112. Tsimihodimos V, Kakafika A, Elisaf M. Fibrate treatment can increase serum creatinine levels. Nephrol Dial Transplant 2001; 16: 1301
113. Filippatos TD, Elisaf MS. Recommendations for severe hypertriglyceridemia treatment, are there new strategies? Curr Vasc Pharmacol 2014; 12: 598-616
114. Keidar S, Guttmann H, Stam T, et al. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. Pharmacoepidemiol Drug Saf 2007; 16: 1192-4
115. Linz PE, Lovato LC, Byington RP, et al. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care 2014; 37: 686-93
116. Kiortsis DN, Filippatos TD, Mikhailidis DP, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007; 195: 7-16
117. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database. BMJ 2010; 340: c2197
118. Klein BE, Klein R, Lee KE, et al. Statin use and incident nuclear cataract. JAMA 2006; 295: 2752-8
119. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ 2014; 349: g3743
120. Harris ML, Bron AJ, Brown NA, et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br J Ophthalmol 1995; 79: 996-1002
121. Chew EY, Davis MD, Danis RP, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology 2014; 121: 2443-51
122. Pecora V, Nucera E, Aruanno A, et al. Delayed-type hypersensitivity to fenofibrate. J Investig Allergol Clin Immunol 2012; 22: 304-5
123. Gardeazabal J, Gonzalez M, Izu R, et al. Phenofibrate-induced lichenoid photodermatitis. Photodermatol Photoimmunol Photomed 1993; 9: 156-8
124. Adams AE, Bobrove AM, Gilliam AC. Statins and "chameleon-like" cutaneous eruptions: simvastatin-induced acral cutaneous vesiculobullous and pustular eruption in a 70-year-old man. J Cutan Med Surg 2010; 14: 207-11
125. Peramiquel L, Serra E, Dalmau J, et al. Occupational contact dermatitis from simvastatin. Contact Dermat 2005; 52: 286-7
126. Oskay T, Kutluay L. Acute generalized exanthematous pustulosis induced by simvastatin. Clin Exp Dermatol 2003; 28: 558-9
127. Granados MT, de la Torre C, Cruces MJ, et al. Chronic actinic dermatitis due to simvastatin. Contact Dermat 1998; 38: 294-5
128. Morimoto K, Kawada A, Hiruma M, et al. Photosensitivity to simvastatin with an unusual response to photopatch and photo tests. Contact Dermat 1995; 33: 274
129. Roger D, Rolle F, Labrousse F, et al. Simvastatin-induced lichenoid drug eruption. Clin Exp Dermatol 1994; 19: 88-9
130. Safrano L, Bourneau-Martin D, Le Clech C, et al. Suspicion of fenofibrate-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: A case report. Therapie 2014; 69: 461-4
131. Rabasa-Lhoret R, Rasamisoa M, Avignon A, et al. Rare side-effects of fenofibrate. Diabetes Metab 2001; 27: 66-8
132. Ruger RD, Simon JC, Treudler R. Subacute-cutaneous lupus erythematosus induced by simvastatin. J Dtsch Dermatol Ges 2011; 9: 54-5
133. Bellini V, Assalve D, Lisi P. Urticarial vasculitis from simvastatin: what is the alternative drug? Dermatitis 2010; 21: 223-4
134. Fauchais AL, Iba Ba J, Maurage P, et al. [Polymyositis induced or associated with lipid-lowering drugs: five cases]. Rev Med Interne 2004; 25: 294-8
135. De Groot RE, Willems LN, Dijkman JH. Interstitial lung disease with pleural effusion caused by simvastin. J Intern Med 1996; 239: 361-3
136. Lantuejoul S, Brambilla E, Brambilla C, et al. Statin-induced fibrotic nonspecific interstitial pneumonia. Eur Respir J 2002; 19: 577-80
137. Lv HL, Jin DM, Liu M, et al. Long-term efficacy and safety of statin treatment beyond six years: A metaanalysis of randomized controlled trials with extended follow-up. Pharmacol Res 2014; 81: 64-73
138. Bonovas S, Nikolopoulos GK, Bagos PG. Use of fibrates and cancer risk: A systematic review and meta-analysis of 17 long-term randomized placebocontrolled trials. PLoS ONE 2012; 7: e45259
139. Winsemius A, Ansquer JC, Olbrich M, et al. Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter? J Clin Pharmacol 2014; 54: 1038-47
140. Penn R, Williams RX, Guha-Ray DK, et al. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. Clin Ther 2006; 28: 45-54
141. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004; 44: 1054-62
142. Watkins JL, Atkinson BJ, Pagliaro LC. Rhabdomyolysis in a prostate cancer patient taking ketoconazole and simvastatin: Case report and review of the literature. Ann Pharmacother 2011; 45: e9
143. Molden E, Skovlund E, Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug Saf 2008; 31: 587-96
144. Itakura H, Vaughn D, Haller DG, et al. Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer. J Urol 2003; 169: 613
145. McKelvie PA, Dennett X. Myopathy associated with HMG-CoA reductase inhibitors (statins): A series of 10 patients and review of the literature. J Clin Neuromuscul Dis 2002; 3: 143-8
146. Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 1999; 22: 295-7
147. Roques S, Lytrivi M, Rusu D, et al. Rhabdomyolysis-induced acute renal failure due to itraconazole and simvastatin association. Drug Metabol Drug Interact 2011; 26: 79-80
148. Saliba WR, Elias M. Severe myopathy induced by the co-administration of simvastatin and itraconazole. Eur J Intern Med 2005; 16: 305
149. Krishna G, Ma L, Prasad P, et al. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin Drug Metab Toxicol 2012; 8: 1-10
150. Page SR, Yee KC. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. Intern Med J 2014; 44: 690-3
151. Wagner J, Suessmair C, Pfister HW. Rhabdomyolysis caused by co-medication with simvastatin and clarithromycin. J Neurol 2009; 256: 1182-3
152. Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy 2007; 27: 603-7
153. Fallah A, Deep M, Smallwood D, et al. Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications. Australas Med J 2013; 6: 112-14
154. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-82
155. Chauvin B, Drouot S, Barrail-Tran A, et al. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet 2013; 52: 815-31
156. Karnik NS, Maldonado JR. Antidepressant and statin interactions: A review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics 2005; 46: 565-8
157. Florentin M, Elisaf MS. Simvastatin interactions with other drugs. Expert Opin Drug Saf 2012; 11: 439-44
158. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004; 58: 56-60
159. Kyrklund C, Backman JT, Kivisto KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68: 592-7
160. Scarfia RV, Clementi A, Granata A. Rhabdomyolysis and acute kidney injury secondary to interaction between simvastatin and cyclosporine. Ren Fail 2013; 35: 1056-7
161. Yang WH, Zeng ZS, Ren XW, et al. Simvastatin-induced myopathy with concomitant use of cyclosporine: case report. Int J Clin Pharmacol Ther 2011; 49: 772-7
162. Tong J, Laport G, Lowsky R. Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Bone Marrow Transplant 2005; 36: 739-40
163. Hsu WC, Chen WH, Chang MT, et al. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol 2002; 25: 266-8
164. Herring R, Caldwell G, Wade S. Rhabdomyolysis caused by an interaction of simvastatin and fusidic acid. BMJ Case Rep 2009; 2009
165. Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust 2003; 179: 172
166. Oh DH, Chan SQ, Wilson AM. Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin. Med J Aust 2012; 197: 332-3
167. Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol 2007; 13: 266-8
168. FDA drug safety communication. 2011. Available from: http: //www. fda. gov/Drugs/DrugSafety/ucm256581. htm [Accessed at 30 March 2015]
169. FDA drug safety communication. 2013. Available from: http: //www. fda. gov/Safety/MedWatch/SafetyInformation/ ucm342600. htm [Accessed at 30 March 2015]